-
1
SF3B1-mutant MDS as a distinct disease subtype: a proposal from the International Working Group for the Prognosis of MDS
Published 2020“…American Society of Hematology…”
Journal article -
2
Repressed chromatin drives leukaemogenesis in mutant IDH2 acute myeloid leukaemia via inhibition of granulocyte differentiation and cell cycle progression
Published 2021“…American Society of Hematology…”
Conference item -
3
A phase 2, open-label, multiarm, multicenter study to evaluate magrolimab combined with antileukemia therapies for first-line, relapsed/refractory, or maintenance treatment of acut...
Published 2021“…American Society of Hematology…”
Conference item -
4
Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia
Published 2017“…American Society of Hematology…”
Journal article -
5
Outcomes for patients with late-stage mutant-IDH2 (m IDH2) relapsed/refractory acute myeloid leukemia (R/R AML) treated with enasidenib vs other lower-intensity therapies in the ra...
Published 2021“…American Society of Hematology…”
Conference item -
6
Characterization of factors determining the kinetics of disease relapse after allogeneic Stem Cell Transplantation (allo-SCT) or chemotherapeutic consolidation for Acute Myeloid Le...
Published 2016“…American Society of Hematology…”
Conference item -
7
Sensitive, rapid diagnostic test for transient abnormal myelopoiesis and myeloid leukemia of Down syndrome
Published 2020“…American Society of Hematology…”
Journal article -
8
Outcomes of relapsed/refractory patients with IDH1/2 mutated AML treated with non-targeted therapy: results from the NCRI AML trials
Published 2018“…American Society of Hematology…”
Conference item -
9
Modelling the progression of a preleukemic stage to overt leukemia in children with down syndrome
Published 2018“…American Society of Hematology…”
Conference item -
10
Vorinostat does not improve outcome in patients with acute myeloid leukemia and high risk myelodysplasia treated with azacitidine: Results of the UK Trials Acceleration Programme R...
Published 2016“…American Society of Hematology…”
Conference item -
11
Fractionated vs single-dose gemtuzumab ozogamicin with determinants of benefit in older patients with AML: the UK NCRI AML18 trial
Published 2023“…American Society of Hematology…”
Journal article -
12
Health-related quality of life (HRQoL) during treatment with enasidenib (ENA) plus azacitidine (AZA) in patients with newly diagnosed mutant IDH2 (m IDH2) acute myeloid leukemia (A...
Published 2021“…American Society of Hematology…”
Conference item -
13
A novel model of human hemopoiesis based on single cell functional and transcriptional analysis of lympho-myeloid progenitors
Published 2017“…American Society of Hematology…”
Conference item -
14
-
15
Single Cell Analysis of Acquired Pomalidomide-Resistance in Multiple Myeloma Cell Lines Reveals Distinct Subclonal Cereblon Mutations and Gene Expression Heterogeneity
Published 2018“…American Society of Hematology…”
Conference item -
16
Mutational analysis of disease relapse in patients allografted for acute myeloid leukemia
Published 2016“…American Society of Hematology…”
Journal article -
17
Human erythroleukemia genetics and transcriptomes identify master transcription factors as functional disease drivers
Published 2020“…American Society of Hematology…”
Journal article -
18
Heterogeneous leukemia stem cells in myeloid blast phase chronic myeloid leukemia
Published 2016“…American Society of Hematology…”
Journal article -
19
A phase 3, randomized, open-label study evaluating the safety and efficacy of magrolimab in combination with azacitidine in previously untreated patients with TP53-mutant acute mye...
Published 2021“…American Society of Hematology…”
Conference item -
20
Loss Of COP9-signalosome genes Aa 2q37 is associated with IMiD agent resistance in multiple myeloma
Published 2022“…American Society of Hematology…”
Journal article